Antibiotics - Global Strategic Business Report

Description: This report analyzes the worldwide markets for Antibiotics in US$ Million by the following product segments: Penicillin, Cephalosporins, Macrolides, Quinolones, Carbapenems, and Other Antibiotics (Aminoglycosides, Tetracyclines, Sulfonamides, Mupirocin, Glycopeptides, Synercid, and Oxazolidinones). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets. The report profiles 197 companies including many key and niche players such as Abbott Laboratories, Astellas Pharma, Inc., Bayer HealthCare AG, Bristol-Myers Squibb Co., Cubist Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Eli Lilly and Co., GlaxoSmithKline Plc, Johnson & Johnson, Kyorin Pharmaceutical Co., Ltd., LG Life Sciences Limited, MiddleBrook™ Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Pliva d.d., Roche, Sanofi-Aventis SA, Takeda Pharmaceutical Company, Ltd., and Toyama Chemical Co., Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For information on site licence pricing please click on Enquire before buying

Contents:

ANTIBIOTICS
A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS .......................... 1
   Study Reliability and Reporting Limitations .............................................. 1
   Disclaimers ......................................................................................... 2
   Data Interpretation & Reporting Level ..................................................... 2
   Quantitative Techniques & Analytics ....................................................... 3
   Product Definitions and Scope of Study ................................................... 3
   Penicillin .............................................................................................. 4
   Cephalosporins .................................................................................... 4
   Macrolides ............................................................................................ 4
   Quinolones ............................................................................................ 4
   Carbapenems ....................................................................................... 4
   Other Antibiotics ................................................................................... 5
   Aminoglycosides .................................................................................... 5
   Tetracyclines ........................................................................................ 5
   Sulfonamides ......................................................................................... 5
   Mupirocin .............................................................................................. 5
   Glycopeptides ....................................................................................... 5
   Synercid ............................................................................................... 6
   Oxazolidinones ..................................................................................... 6
   Linezolid .............................................................................................. 6

2. INDUSTRY OVERVIEW ........................................................................ 7
   Antibiotic Resistance and Generic Competition to Impact Long Term Growth ............................................................................... 7
   New Regulations Guiding Usage of Drugs to Drive Growth ....................... 7
3. MARKET DYNAMICS

- Anti-Bacterials Segment Drives Global Anti-Infectives Market
- Antibiotic Resistance - A Primary Growth Inhibitor
- Antibiotic-Resistant Bacteria by Type
- Patent Expiries Commoditize Antibiotics
- Anti-MRSA Antibiotics Find Their Way

Table 1: World MRSA Treatments (2007 & 2008): Percentage Share Breakdown by Leading Antibiotic Drugs - Vancomycin, Zyvox, Cubicin and Tygacil (includes corresponding Graph/Chart)

4. COMPETITION

- Highly Competitive Market

Table 2: Leading Players in the Worldwide Antibiotics Market (2008): Percentage Breakdown by Value Sales for Pfizer, GlaxoSmithKline, Sanofi-aventis, Johnson & Johnson, Bayer, Abbott, Wyeth, and Others (includes corresponding Graph/Chart)

GlaxoSmithKline - The Undisputed Leader of Penicillin Market

Table 3: Worldwide Leading Antibiotics within Penicillin Class (2005 & 2006): Percentage Breakdown by Value for Augmentin, Zosyn/Tazocin, Amoxil, and Others (includes corresponding Graph/Chart)

GlaxoSmithKline Leads Cephalosporin Market

Table 4: Worldwide Leading Antibiotics within Cephalosporin Class (2005 & 2006): Percentage Breakdown by Value for Rocephin, Ceftin/Zinnat, Flomox, Fortum/Fortaz, Cefzil, Cefzon, Flumarin, and Others (includes corresponding Graph/Chart)

Pfizer Dominates Macrolides Market

Table 5: Worldwide Leading Antibiotics within Macrolide Class (2005 & 2006): Percentage Breakdown by Value for Zithromax, Klaricid/Biaxin, Ketek, and Others (includes corresponding Graph/Chart)

Levaquin/Tavanic - The Most Preferred Quinolone Antibiotic

Table 6: Worldwide Leading Antibiotics within Quinolone Class (2005 & 2006): Percentage Breakdown by Value for Levaquin/Tavanic, Avelox, Ciprobay/Ciproxin, Cravid, and Others (includes corresponding Graph/Chart)

Merck Rules Carbapenems Market

Table 7: Worldwide Leading Antibiotics within Carbapenem Class (2005 & 2006): Percentage Breakdown by Value for Primaxin, Merrem, Invanz, and Others (includes corresponding Graph/Chart)

5. PRODUCT OVERVIEW

- Antibiotics - An Introduction
- Antibiotic Resistance
- b-Lactams
- Classification of Antibiotics
- Key Milestones in Antibiotic Development
- Antibiotic Types
- Penicillin
- History
- About the Drug
- Cephalosporins
- Treatment
- Effects of the Drug
- Macrolides
### Treatment

1. **Quinolones**  
2. **Carbapenems**  
3. **Other Antibiotics**  
4. **Aminoglycosides**  
5. **Tetracyclines**  
6. **Sulfonamides**  
7. **Mupirocin**  
8. **Glycopeptides**  
9. **Oxazolidinones**  
10. **Linezolid**

### 6. RESEARCH FINDINGS

1. New Design for Monitoring Toxin Delivery Activity of Pathogenic Bacteria
2. Cephalosporins Effective when Compared to Penicillin
3. FDA Bans Baytril Antibiotic for Chickens
4. Erythromycin Along with Some Specific Drugs Increase Risk of Sudden Death
5. Rise in Usage of Quinolones for Urinary Tract Infections Leads to Drug Resistance
6. Polyphor Discovers POL7080 - New Antibiotic Against Gram-Negative Bacteria

### 7. FDA APPROVALS/PATENTS

1. MiddleBrook Obtains NDA Approval for MOXATAG™
2. J&JPRD Seeks FDA Approval for Doripenem Antibiotic
3. J&JPRD Seeks FDA Approval for Investigational Antibiotic, Ceftobiprole
4. GSK Receives Approval for ALTARGO® in Europe
5. APL Receives FDA Approval for Cefpodoxime Proxetil
6. Cubist Receives Approval to Market CUBICIN in Canada
7. Cubist Obtains Approval to Market CUBICIN for Added Indications in EU
8. Cubist Gains Approval for CUBICIN in Taiwan and South Korea
9. Cethromycin Achieves FDA’s Orphan Drug Designation
10. FD approves Wockhardt’s Cefotaxime Injection
11. FDA Approves Doxycycline Tablets
12. FDA Approves Clarithromycin
13. FDA Approves Doxycycline Tablets For The US Market
14. Johnson & Johnson Applies Doripenem For FDA Approval
15. FDA Certifies Antibiotics do Brasil’s Plant
16. FDA Certifies ANDA For Cefdinir Capsules
17. US FDA Approves Teva’s Cefprozil Tablets
18. FDA Certifies ANDA for Cephalexin Capsules
19. American Pharmaceutical Partners Receives FDA Approvals for Ceftriaxone for Injection, USP
20. Advancis’s Keflex Receives FDA Approval
21. Wockhardt Gains Marketing Approval for Cefuroxime axetil in the US
22. Wyeth’s Mylotarq Receives Government’s Approval
23. FDA Approves Generic Version of Zithromax
24. Pfizer Wins FDA Approval for Zmax™
25. Venus Remedies Files Second PCT for New Cephalosporins
Falcon Gains US FDA Approval for its Generic Anti-Infective Solution 36
Cadilla Receives FDA Approval to Market Clindamycin 36

8. RECENT INDUSTRY ACTIVITY 37
DSM Opens Eco-friendly Antibiotics Plant ZOR-f, in the Netherlands 37
Daiichi Leverages Ranbaxy's Network to Market Tavanic in South Africa and Romania 37
Pfizer Acquires Wyeth 37
Durata Therapeutics Acquires Pfizer's Vicuron Pharmaceuticals 37
Cubist Completes Acquisition of Calixa Therapeutics 38
AstraZeneca to Acquire Novexel 38
Tianyin and Sichuan Mingxin to Establish an Antibiotic Joint Venture 38
Pfizer and Aurobindo Pharma Ink Agreement for Producing Off Patent Drugs 39
BMP Sunstone to Acquire Majority Stake in Zhangjiakou Shengda 39
Novartis to Take Over Protez Pharmaceuticals 39
3i to Buy Alpharma Unit 40
NCPC to Acquire Stake in DSM's Antibiotics Division 40
ULL Establishes New Antibiotics Unit in Himachal Pradesh 40
Biocat to Expand Presence in the Indian Market 40
PRWT Acquires Cherokee Chemical Unit from Merck 40
CSPC Joins Hands with Indonesian Firms 41

9. STRATEGIC CORPORATE DEVELOPMENTS IN THE RECENT PAST - A PERSPECTIVE BUILDER 42
Nisshin-Kyorin to Merge with Kyorin Pharmaceutical 42
Schering-Plough Acquires Organon BioSciences 42
GSK & Anacor Partner for Boron Chemistry-Based Antibiotics and Antivirals 42
Iroko Bags Canadian Rights to Vancocin® 43
Cubist Licenses CUBICIN Rights to Merck 43
Sagent Partners with Astral to Develop Injectable Antibiotics 43
MR Healthcare to Manufacture New Antibiotics & Medicines 43
Livzon Synthetic to Acquire Antibiotic Intermediate from Jiaozuo 44
C&O Pharmaceutical to Distribute Meiact in China 44
Bioton Signs Deal to Market Antibiotics in Russia 44
Toyama Gains Marketing Approval for Geninax® in Japan 44
Forest Laboratories Acquires Cerexa 44
Oscient Modifies Licensing Agreement With LG Life Sciences 44
Orchid Sign Licensing & Distribution Pact With Actavis 45
Forest Laboratories Revokes Partnership With Replidyne 45
SRI and Blanca Collaborate To Develop & Test Carbacephem 45
AstraZeneca To Expand Research Center For Antibiotics 45
Jade Pharmaceutical Begins Levofloxacin's Production in China 45
Reyoung To Start Antibiotic Production At New Facility 46
Toyama Begins T-705 Clinical Trials 46
SmPC For Sanofi-Aventis' Ketek® Updated 46
Lupin Receives Approval for Cefpodoxime Proxetil Antibiotic Tablets in France 46
Antibiotice Plans To Infuse Funds For Antibiotics Production 46
UAE Approves Pfizer's Zithromax SD 46

10. PRODUCT INNOVATIONS/INTRODUCTIONS 47
Janssen-Cilag Launches Doribax™ - New Carbapenem Antibiotic 47
MIT Scientists Develop a New Antibiotic, Rhodostreptomycin 47
Watson Pharma Introduces Biaxin XL's Generic Version 47

11. PRODUCT INNOVATIONS IN THE RECENT PAST - A PERSPECTIVE BUILDER 48
Toyama Launches New Garenoxacin Quinolone Antibiotic 48
Wockhardt to Introduce Cefprozil in the US 48
MSD India Launches Invanza in India
Orchid Chemicals to Introduce Three New Drugs in the US
DUSA Pharmaceuticals Releases ClindaReach™
Mylan Releases Cipro’s Generic Version
Macrolide Antibiotic Developed In the US
University of Michigan Devises NMR Spectroscopy For Antibiotics
Glycopeptide-Cephalosporin Antibiotics Developed In The US
Neosil Tests NEO 101 Antibiotic
New Antibiotic Developed By Canadian Inventors
Abbott Canada Releases FACTIVE® Antibiotic Tablets In Canada
Penicillin Binding Protein Found In Japan
Venus Remedies Releases Mucomelt-Forte

12. FOCUS ON SELECT GLOBAL PLAYERS
Abbott Laboratories (USA)
Astellas Pharma, Inc. (Japan)
Bayer HealthCare AG (Germany)
Bristol-Myers Squibb Co. (USA)
Cubist Pharmaceuticals, Inc. (USA)
Daiichi Sankyo Company, Limited (Japan)
Eli Lilly and Co. (USA)
GlaxoSmithKline Plc (UK)
Johnson & Johnson (USA)
Kyorin Pharmaceutical Co., Ltd. (Japan)
LG Life Sciences Limited (Korea)
MiddleBrook™ Pharmaceuticals, Inc. (USA)
Novartis AG (Switzerland)
Pfizer Inc. (USA)
Pliva d.d. (Croatia)
Roche (Switzerland)
Sanofi-Aventis SA (France)
Takeda Pharmaceutical Company, Ltd. (Japan)
Toyama Chemical Co., Ltd. (Japan)

13. GLOBAL MARKET PERSPECTIVE
Table 9: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 10: World Historic Review for Antibiotics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)
Table 11: World 11-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)
Table 12: World Recent Past, Current & Future Analysis for Penicillin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 13: World Historic Review for Penicillin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006
Table 14: World 11-Year Perspective for Penicillin by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)  

Table 15: World Recent Past, Current & Future Analysis for Cephalosporin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)  

Table 16: World Historic Review for Cephalosporin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)  

Table 17: World 11-Year Perspective for Cephalosporin by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)  

Table 18: World Recent Past, Current & Future Analysis for Macrolides by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)  

Table 19: World Historic Review for Macrolides by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)  

Table 20: World 11-Year Perspective for Macrolides by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)  

Table 21: World Recent Past, Current & Future Analysis for Quinolones by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)  

Table 22: World Historic Review for Quinolones by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)  

Table 23: World 11-Year Perspective for Quinolones by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)
Table 24: World Recent Past, Current & Future Analysis for Carbapenems by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart) 76

Table 25: World Historic Review for Carbapenems by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart) 77

Table 26: World 11-Year Perspective for Carbapenems by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart) 78

Table 27: World Recent Past, Current & Future Analysis for Other Antibiotics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart) 79

Table 28: World Historic Review for Other Antibiotics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart) 80

Table 29: World 11-Year Perspective for Other Antibiotics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart) 81

14. THE UNITED STATES 82
A. Market Analysis 82
Current and Future Analysis 82
Antibiotics Approved Between 2000 and 2005 in the United States 82
Competition 83
Table 30: Leading Players in the US Antibiotics Market (2008): Percentage Breakdown by Value Sales for Pfizer, Johnson & Johnson, GlaxoSmithKline, Abbott, and Others (includes corresponding Graph/Chart) 83
Key Players 83
B. Market Analysis 84
Table 31: US Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart) 84
Table 32: US Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart) 85
Table 33: US 11-Year Perspective for Antibiotics by Product
Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart) 86

15. CANADA 87
A. Market Analysis 87
  Current And Future Analysis 87
B. Market Analytics 87
  Table 34: Canadian Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart) 87

  Table 35: Canadian Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart) 88

  Table 36: Canadian 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart) 89

16. JAPAN 90
A. Market Analysis 90
  Current and Future Analysis 90
  Key Players 90
B. Market Analytics 91
  Table 37: Japanese Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart) 91

  Table 38: Japanese Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart) 92

  Table 39: Japanese 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart) 93

17. EUROPE 94
A. Market Analysis 94
  Current and Future Analysis 94
B. Market Analytics 95
  Table 40: European Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart) 95
Table 41: European Historic Review for Antibiotics by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart) 96

Table 42: European Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems, and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart) 97

Table 43: European Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems, and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart) 98

Table 44: European 11-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart) 99

Table 45: European 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems, and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart) 100

17a. FRANCE 101
A. Market Analysis 101
  Current and Future Analysis 101
  Trends 101
  Over Consumption of Antibiotics - Cause of Concern 101
  Sanofi-Aventis SA - A Key Player 101
B. Market Analytics 102
Table 46: French Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart) 102

Table 47: French Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart) 103

Table 48: French 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart) 104

17b. GERMANY 105
A. Market Analysis 105
  Current and Future Analysis 105
  Bayer HealthCare AG - A Key Player 105
17c. ITALY

A. Market Analysis
   109
   Current and Future Analysis

B. Market Analytics
   109
   Table 52: Italian Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
   109

   Table 53: Italian Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)
   110

   Table 54: Italian 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)
   111

17d. THE UNITED KINGDOM

A. Market Analysis
   112
   Current And Future Analysis

B. Market Analytics
   113
   Table 55: UK Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
   113

   Table 56: UK Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, acrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)
   114

   Table 57: UK 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for
Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart) 115

17e. SPAIN 116
Market Analysis 116
Table 58: Spanish Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart) 116

Table 59: Spanish Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart) 117

Table 60: Spanish 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart) 118

17f. REST OF EUROPE 119
A. Market Analysis 119
Current and Future Analysis 119
Poland 119
Table 61: Polish Market for Antibiotics (2008): Percentage Breakdown of Market Share by Leading Companies - GSK Pharma, Bioton, Sandoz Corp, Ranbaxy and Others (includes corresponding Graph/Chart) 119
Focus On Select Players 119
B. Market Analytics 120
Table 62: Rest of Europe Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart) 120

Table 63: Rest of Europe Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart) 121

Table 64: Rest of Europe 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart) 122

18. ASIA-PACIFIC 123
A. Market Analysis 123
Current and Future Analysis 123
India 123
Rising Prices of Penicillin G to Affect Antibiotics Production 123
Market for Injectable Antibiotics Poised to Grow 123
Cipla, Pharmaceutical Market Leader in 2009 124
China 124
Carbapenem Witnesses Robust Growth in China 124
Key Players 125
Ranbaxy Laboratories Ltd. (India) 125
B. Market Analytics 126
Table 65: Asia-Pacific Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart) 126

Table 66: Asia-Pacific Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart) 127

Table 67: Asia-Pacific 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart) 128

19. REST OF WORLD 129
A. Market Analysis 129
Current and Future Analysis 129
B. Market Analytics 130
Table 68: Rest of World Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart) 130

Table 69: Rest of World Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart) 131

Table 70: Rest of World 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart) 132

COMPETITION

Total Companies Profiled: 197 (including Divisions/Subsidiaries - 238)

---------
Region/Country Players
---------
The United States 48
Canada 8
Japan 11
Europe 68
France 7
Germany 10
The United Kingdom 8
Italy                                10
Spain                                 4
Rest of Europe                        29
Asia-Pacific (Excluding Japan)         87
Middle East                            11
Latin America                         4
Africa                                 1

Ordering:

Order Online - http://www.researchandmarkets.com/reports/358604/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Antibiotics - Global Strategic Business Report
Web Address: http://www.researchandmarkets.com/reports/358604/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 4500</td>
</tr>
<tr>
<td>Hard Copy:</td>
<td>USD 4500 + USD 61 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 15 Users:</td>
<td>USD 10800</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 10 Users:</td>
<td>USD 8550</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users:</td>
<td>USD 6300</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.
* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □
First Name: __________________________ Last Name: __________________________
Email Address: * __________________________
Job Title: __________________________
Organisation: __________________________
Address: __________________________
City: __________________________
Postal / Zip Code: __________________________
Country: __________________________
Phone Number: __________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by Wire Transfer: Bank details will be provided on the invoice which you will receive after you place your order with us.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World